PE20151717A1 - Compuestos lipopeptidos y metodos relacionados - Google Patents

Compuestos lipopeptidos y metodos relacionados

Info

Publication number
PE20151717A1
PE20151717A1 PE2015002039A PE2015002039A PE20151717A1 PE 20151717 A1 PE20151717 A1 PE 20151717A1 PE 2015002039 A PE2015002039 A PE 2015002039A PE 2015002039 A PE2015002039 A PE 2015002039A PE 20151717 A1 PE20151717 A1 PE 20151717A1
Authority
PE
Peru
Prior art keywords
related methods
lipopeptide compounds
reducing sugar
daptomycin
lipopeptide
Prior art date
Application number
PE2015002039A
Other languages
English (en)
Inventor
Sandra O'connor
Sophie Sun
Gaauri Naik
Original Assignee
Cubist Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44060422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151717(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharm Inc filed Critical Cubist Pharm Inc
Publication of PE20151717A1 publication Critical patent/PE20151717A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Referida a una composicion farmaceutica que comprende: (a) daptomicina; y (b) al menos un excipiente seleccionado de glicina y un azucar no reductor, donde a relacion molar de daptomicina al azucar no reductor es 1:1,12 a 1:21,32 y el azucar no reductor se selecciona de trehalosa, sacarosa y manitol
PE2015002039A 2009-11-23 2010-11-23 Compuestos lipopeptidos y metodos relacionados PE20151717A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26378409P 2009-11-23 2009-11-23

Publications (1)

Publication Number Publication Date
PE20151717A1 true PE20151717A1 (es) 2015-11-19

Family

ID=44060422

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015002039A PE20151717A1 (es) 2009-11-23 2010-11-23 Compuestos lipopeptidos y metodos relacionados
PE2012000703A PE20121517A1 (es) 2009-11-23 2010-11-23 Compuestos lipopeptidos y metodos relacionados

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2012000703A PE20121517A1 (es) 2009-11-23 2010-11-23 Compuestos lipopeptidos y metodos relacionados

Country Status (33)

Country Link
US (3) US8835382B2 (es)
EP (2) EP3417849A1 (es)
JP (3) JP6041673B2 (es)
CN (3) CN104056250A (es)
AR (2) AR079127A1 (es)
AU (1) AU2010321531C1 (es)
BR (1) BR112012012406B1 (es)
CA (1) CA2781666C (es)
CL (2) CL2012001336A1 (es)
CO (1) CO6541585A2 (es)
CR (1) CR20120271A (es)
CY (1) CY1120854T1 (es)
DK (1) DK2504353T4 (es)
DO (1) DOP2012000140A (es)
EC (1) ECSP12011939A (es)
ES (1) ES2686331T5 (es)
FI (1) FI2504353T4 (es)
HR (1) HRP20181380T4 (es)
HU (1) HUE039967T2 (es)
IL (1) IL219891B (es)
LT (1) LT2504353T (es)
MX (1) MX2012005993A (es)
NZ (1) NZ600118A (es)
PE (2) PE20151717A1 (es)
PL (1) PL2504353T5 (es)
PT (1) PT2504353T (es)
RS (1) RS57566B2 (es)
RU (1) RU2607526C2 (es)
SG (1) SG10201407724YA (es)
SI (1) SI2504353T2 (es)
TR (1) TR201812823T4 (es)
TW (2) TWI606838B (es)
WO (1) WO2011063419A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
FI2504353T4 (fi) 2009-11-23 2023-11-30 Cubist Pharmaceuticals Llc Lipopeptidikoostumukset ja vastaavat menetelmät
DK2661254T3 (da) 2011-01-05 2017-11-06 Hospira Inc Sprøjtetørring af vancomycin
MX2013013760A (es) * 2011-05-26 2014-01-08 Cubist Pharm Inc Composiciones de cb-183, 315 y metodos relacionados.
JP6170946B2 (ja) * 2012-01-12 2017-07-26 セルジーン コーポレイション ロミデプシン製剤及びその使用
BR112015003198A2 (pt) * 2012-08-23 2017-10-10 Mylan Laboratories Ltd formulação injetável de daptomicina melhorada.
ES2552754T1 (es) 2012-09-11 2015-12-02 Hospira Australia Pty Ltd Formulaciones de daptomicina y usos de la misma
CN104027791B (zh) * 2013-03-06 2016-08-10 浙江海正药业股份有限公司 药物组合物
CN104511011A (zh) * 2013-09-29 2015-04-15 山东新时代药业有限公司 一种达托霉素无菌粉末及其制备方法
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10933019B2 (en) 2016-10-21 2021-03-02 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
MX2020001885A (es) 2017-08-31 2020-09-07 Xellia Pharmaceuticals Aps Formulaciones de daptomicina.
CN110339341A (zh) * 2018-04-03 2019-10-18 江苏恒瑞医药股份有限公司 一种达托霉素或其盐的组合物
CN110548130A (zh) * 2018-06-04 2019-12-10 浙江医药股份有限公司新昌制药厂 含达托霉素的喷雾干粉及其工业化制备方法
US11058745B1 (en) 2018-10-04 2021-07-13 Good Health, Llc Stable liquid pharmaceutical compositions of daptomycin
CN111840511A (zh) * 2019-04-30 2020-10-30 江苏恒瑞医药股份有限公司 一种含有精氨酸的达托霉素或其盐的组合物
JPWO2021131314A1 (es) * 2019-12-26 2021-07-01
MX2022010378A (es) 2020-02-28 2022-09-21 Xellia Pharmaceuticals Aps Formulacion de daptomicina.
CA3170514A1 (en) * 2020-03-12 2021-09-16 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
US11362190B2 (en) 2020-05-22 2022-06-14 Raytheon Company Depletion mode high electron mobility field effect transistor (HEMT) semiconductor device having beryllium doped Schottky contact layers
KR102218688B1 (ko) * 2020-06-25 2021-02-22 주식회사 클린텍 무선제어기능을 구비한 고압세척기
RU2770481C1 (ru) * 2021-06-25 2022-04-18 федеральное государственное автономное образовательное учреждение высшего образования «Казанский (Приволжский) федеральный университет» (ФГАОУ ВО КФУ) Способ получения суммарной фракции липопептидов бактерий Bacillus subtilis MG-8 ВКПМ В-12476 и его использование в качестве профилактического средства от болезней сельскохозяйственных птиц

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331594A (en) 1978-10-16 1982-05-25 Eli Lilly And Company A-21978 Antibiotics and process for their production
EP0014815A3 (de) 1978-12-20 1980-10-29 Ciba-Geigy Ag Peptidderivate, Verfahren zu deren Herstellung und Zwischenprodukte sowie pharmazeutische Präparate mit einer dieser Verbindungen
US4432487A (en) 1982-01-18 1984-02-21 Chugai Denki Kogyo Kabushiki Kaisha Method of overlaying stainless steel material for decorative articles and ornaments with a precious metal alloy
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
DD238068A5 (de) 1984-10-09 1986-08-06 ���@�����@�K@�������k�� Verfahren zur herstellung von derivaten der cyclopeptidantibiotika a-21978 c
CA1319886C (en) 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
CA1315229C (en) 1987-06-10 1993-03-30 Patrick J. Baker Chromatographic purification process
US4874843A (en) * 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
EP0294990A3 (en) 1987-06-10 1990-05-09 Eli Lilly And Company Chromatographic purification process
US5271935A (en) 1988-02-05 1993-12-21 Hoechst Aktiengesellschaft Antibiotic, cammunocin, a process for the preparation thereof, and the use thereof as a pharmaceutical
NZ232763A (en) * 1989-03-06 1991-09-25 Lilly Co Eli Parenteral formulation comprising daptomycin with a buffer to maintain ph between 6.0 and 8.0
DE69031730T2 (de) 1990-01-26 1998-04-23 Hoechst Ag Neues Antibiotikum, Deoxymulündocandin, Verfahren zu seiner Produktion und Verwendung als Medikament
JPH04224197A (ja) 1990-12-26 1992-08-13 Fujitsu Ltd 生体高分子結晶化方法および装置
US5336756A (en) 1991-05-01 1994-08-09 Merck & Co., Inc. Process for crystalline cyclic lipopeptides
TW213468B (es) 1991-06-29 1993-09-21 Hoechst Ag
JP2948708B2 (ja) 1991-11-27 1999-09-13 ニューヨーク・ブラッド・センター・インコーポレーテッド フィブロネクチン含有点眼液
CA2133644C (en) 1992-04-20 2008-09-09 Alexander H. T. Chu Process for making vancomycin
TW455591B (en) 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5952300A (en) 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
US5955509A (en) 1996-05-01 1999-09-21 Board Of Regents, The University Of Texas System pH dependent polymer micelles
JPH10212241A (ja) * 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Ｂｄｎｆを安定に含有する製剤
WO1999027957A1 (en) 1997-12-03 1999-06-10 The Immune Response Corporation Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
FR2771640B1 (fr) 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung
PL206091B1 (pl) 1998-09-25 2010-06-30 Cubist Pharmaceuticals Zastosowania daptomycyny
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
MXPA02006030A (es) 1999-12-15 2004-08-23 Cubist Pharm Inc Lipopeptidos como agentes antibacterianos.
US6696412B1 (en) * 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
WO2001097851A2 (en) * 2000-06-21 2001-12-27 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
US6716962B2 (en) 2000-07-17 2004-04-06 Micrologix Biotech Inc. Extractive purification of lipopeptide antibiotics
KR20080036661A (ko) * 2000-12-18 2008-04-28 큐비스트 파마슈티컬즈 인코포레이티드 정제된 리포펩티드의 제조 방법
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
WO2002059145A1 (en) 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
JP3932272B2 (ja) * 2001-06-28 2007-06-20 明治乳業株式会社 多重ｔ細胞エピトープポリペプチドの酢酸塩組成物
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
KR20040032891A (ko) 2001-08-06 2004-04-17 큐비스트 파마슈티컬즈 인코포레이티드 답토마이신 생합성 유전자 클러스터에 관련된 조성물 및방법
JP2005514498A (ja) 2002-01-17 2005-05-19 アルケマ 超分子ポリマー
JP2006506442A (ja) 2002-07-09 2006-02-23 ポイント セラピューティクス， インコーポレイテッド ボロプロリン化合物併用療法
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
JP2005060377A (ja) * 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd インターロイキン−１１含有凍結乾燥製剤
US20050152979A1 (en) * 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CN1616083A (zh) * 2004-09-01 2005-05-18 魏雪纹 注射用达托霉素冻干制剂及制备方法
WO2006085337A1 (en) * 2005-02-14 2006-08-17 Venus Remedies Limited Parenteral combination therpy for infective conditions with drug resistant bacterium
WO2006130629A2 (en) 2005-05-31 2006-12-07 Cubist Pharmaceuticals, Inc. Daptomycin for the treatment of biofilm and catheter salvage
CA2611577A1 (en) 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
EP2340846A1 (en) 2006-07-26 2011-07-06 Sandoz Ag Caspofungin formulations
DK2084519T3 (da) 2006-10-10 2012-08-20 Los Alamos Nat Security Llc Røntgenfluorescens-analysefremgangsmåde
DE102007004968B4 (de) * 2007-01-26 2011-03-10 Heraeus Kulzer Gmbh Revisions-Polymethylmethacrylat-Knochenzement
WO2008102452A1 (ja) 2007-02-22 2008-08-28 Kringle Pharma Inc. Ｈｇｆ製剤
EP2150537A4 (en) * 2007-06-01 2010-09-22 Acologix Inc STABLE PEPTIDE FORMULATION AT HIGH TEMPERATURE
JP5537425B2 (ja) 2007-06-26 2014-07-02 メルク・シャープ・アンド・ドーム・コーポレーション 凍結乾燥抗真菌組成物
RU2517140C2 (ru) * 2007-10-25 2014-05-27 Новартис Аг Способ обработки упаковки с однократной дозой лекартвенного препарата
WO2009144739A1 (en) 2008-05-26 2009-12-03 Biocon Limited Amorphous daptomycin and a method of purification thereof
WO2011019839A2 (en) 2009-08-12 2011-02-17 The Medicines Company Glycopeptide and lipoglycopeptide antibiotics with improved solubility
US8431539B2 (en) 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
FI2504353T4 (fi) 2009-11-23 2023-11-30 Cubist Pharmaceuticals Llc Lipopeptidikoostumukset ja vastaavat menetelmät
US20110124551A1 (en) 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
CN103379917B (zh) 2010-11-01 2016-10-12 梅琳塔治疗公司 药物组合物
CA2822447C (en) 2010-12-23 2018-05-01 Alkermes Pharma Ireland Limited Multi-api loading prodrugs
EP2670418A4 (en) 2011-02-04 2015-06-17 Aegis Therapeutics Llc ORAL BIO-AVAILABLE PEPTIDARY MATERIAL COMPOSITIONS AND METHOD THEREFOR

Also Published As

Publication number Publication date
HRP20181380T1 (hr) 2018-10-19
SG10201407724YA (en) 2014-12-30
EP2504353B1 (en) 2018-07-11
PT2504353T (pt) 2018-10-18
CO6541585A2 (es) 2012-10-16
CN108785654A (zh) 2018-11-13
AU2010321531A1 (en) 2012-06-14
DK2504353T4 (da) 2023-11-20
DOP2012000140A (es) 2012-10-30
TWI548414B (zh) 2016-09-11
CN102712677A (zh) 2012-10-03
NZ600118A (en) 2014-08-29
JP6088681B2 (ja) 2017-03-01
PE20121517A1 (es) 2012-11-26
US9662397B2 (en) 2017-05-30
IL219891B (en) 2018-01-31
JP6239167B2 (ja) 2017-11-29
RU2012126076A (ru) 2013-12-27
WO2011063419A3 (en) 2011-10-13
TW201703791A (zh) 2017-02-01
US20160030577A1 (en) 2016-02-04
PL2504353T3 (pl) 2018-11-30
IL219891A0 (en) 2012-07-31
AU2010321531B2 (en) 2016-11-03
AR079127A1 (es) 2011-12-28
AR123846A2 (es) 2023-01-18
DK2504353T3 (en) 2018-09-10
JP2016147874A (ja) 2016-08-18
EP2504353A2 (en) 2012-10-03
TW201141506A (en) 2011-12-01
TWI606838B (zh) 2017-12-01
SI2504353T2 (sl) 2023-11-30
JP6041673B2 (ja) 2016-12-14
EP3417849A1 (en) 2018-12-26
JP2013511557A (ja) 2013-04-04
CA2781666A1 (en) 2011-05-26
RU2607526C2 (ru) 2017-01-10
HUE039967T2 (hu) 2019-02-28
CY1120854T1 (el) 2019-12-11
ECSP12011939A (es) 2012-07-31
US20120270772A1 (en) 2012-10-25
US9138456B2 (en) 2015-09-22
EP2504353B2 (en) 2023-09-13
AU2010321531A2 (en) 2014-10-30
PL2504353T5 (pl) 2023-11-20
CA2781666C (en) 2017-02-21
US8835382B2 (en) 2014-09-16
CL2012001336A1 (es) 2012-10-05
HRP20181380T4 (hr) 2023-11-10
BR112012012406A2 (pt) 2019-12-03
CN104056250A (zh) 2014-09-24
CN102712677B (zh) 2015-06-03
WO2011063419A2 (en) 2011-05-26
EP2504353A4 (en) 2014-04-02
TR201812823T4 (tr) 2019-02-21
MX2012005993A (es) 2012-11-23
CL2015002412A1 (es) 2016-02-05
RS57566B2 (sr) 2023-12-29
CR20120271A (es) 2012-08-01
JP2017075186A (ja) 2017-04-20
RS57566B1 (sr) 2018-10-31
FI2504353T4 (fi) 2023-11-30
LT2504353T (lt) 2018-09-25
SI2504353T1 (sl) 2018-10-30
ES2686331T3 (es) 2018-10-17
BR112012012406B1 (pt) 2021-11-16
US20140364380A1 (en) 2014-12-11
AU2010321531C1 (en) 2020-10-01
ES2686331T5 (es) 2024-03-27

Similar Documents

Publication Publication Date Title
PE20151717A1 (es) Compuestos lipopeptidos y metodos relacionados
CL2012002489A1 (es) Compuestos derivados de sililo nafto-imidazol; composición farmacéutica; y su uso para prevenir o tratar una infección por el virus de la hepatitis c.
CL2012002716A1 (es) Uso de un compuesto inhibidores de dgat1 porque es útil en la prevención, demora del progreso o el tratamiento de una enfermedad o condición seleccionada a partir de quilomicronemia, síndrome de quilomicronemia familiar e hiperlipoproteinemia tipo v; un compuesto derivado de heteroarilo sustituido; composición farmacéutica.
JO3257B1 (ar) مركبات وتركيبات كمعدلات لفاعلية tlr
EA201270356A1 (ru) Иммуногенные композиции, содержащие модуляторы активности tlr
CR20110679A (es) Formulación subcutánea de anticuerpo anti-her2
CO6670598A2 (es) Forma de dosificación resistente a alteración que comprende un polímero aniónico
ECSP13012590A (es) Composiciones bioactivas de chromobacterium y metabolitos
EA201071378A1 (ru) Дронедарон для предотвращения постоянной фибрилляции предсердий
AR062980A1 (es) Composiciones farmaceuticas de compuestos de pirimidil-amino-benzamida
NI201200017A (es) Formulación farmacéutica
ECSP13012755A (es) Composiciones farmacéuticas que contienen un inhibidor de dgat1
BR112012011328A2 (pt) inibidores de akt
EA201171246A1 (ru) Содержащая трегалулозу композиция, ее получение и применение
NI200900053A (es) Composiciones de fenilalquilamino carbamato
UA111599C2 (uk) Композиція каспофунгіну
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
ZA200905690B (en) Compositions comprising peg-interferon alpha conjugates and raffinose as cryoprotectant
EP2611799A4 (en) PHARMACEUTICAL COMPOSITIONS OF LINEZOLID
ZA201102652B (en) Pharmaceutical composition utilising combinations of variants of the gonadotropin-liberating hormane (gnrh) as immunogen
WO2010132693A3 (en) Oligomer-containing pyrrolidine compounds
EA201290319A1 (ru) Применение источника l3 и/или l5 в качестве вакцины или диагностического средства для паразитарного заболевания
ATE533477T1 (de) Pharmazeutische zusammensetzungen enthaltend irbesartan
BRPI0713343A2 (pt) Composições farmacêuticas contendo anticorpo monoclonal anti-idiolípico anti-ca-125 e alumínio
TR201002878A2 (tr) Sefpodoksim proksetil içeren farmasötik bileşimler.